预约演示

Almirall’s Ilumetri shown to improve and maintain well-being in plaque psoriasis patients

2024-07-02

临床结果上市批准

Almirall has presented positive results for Ilumetri (tildrakizumab) in patients with moderate-to-severe plaque psoriasis at the International Federation of Psoriasis Association Conference 2024 in Sweden.

The POSITIVE clinical study has been evaluatIlumetriimtildrakizumab clearance of Ilumetri in 782 adults wplaque psoriasissevere psoriasis and is the first dePsoriasiscal study to use the five-item World Health Organization Wellbeing Index, a questionnaire widely used to assess health-related subjective psychological well-being in a variety of chronic diseases.

Affecting around 60 million people globally, psoriasis is characterised by flaky Ilumetriof skin, of which nearly 77% of patientpsoriasisd that it negatively affects their normal daily activities and well-being.chronic diseases

Ilumetri is a humanised monoclonal antibody tpsoriasis to inhibit the release of proinflammatory cytokines and chemokines without affecting the rest of the immune system.

Ilumetriresults showed that Ilumetri demonstrated notable improvements in skin clearance, particularly in sensitive areas such as the scalp, nail and palms/soles, as well as in high burden symptoms, including itch, pain, joint pain and fatigue, with almost six out of ten patients achieving a Psoriasis Area and Severity Index response of one or below at 52 weeks, with no new safety signals observed, which are consistent with previous studies.

Furthermore, as early as 16 Ilumetrilumetri effectively restored the level of well-being of patients with moderate-to-severe plaque psoriasis to that of the general population, highlighting the importance of uitchstpainngjoint painosocifatigueen of psoriasis beyond the physical symptoms.Psoriasis

Commenting on the results, Dr VolkeIlumetrilny, chief medical officer, Almirall, said: “These findings represent a significanplaque psoriasisur ongoing efforts to address the needs of patients and dermatologists to treat chronic dermatological condipsoriasis help improve the patients’ health and well-being.”

Earlier this year, the company presented preliminary results from the PAlmirallstudy at the 2024 World Congress of Dermatology in Singapore.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构